Sign in →

Test Code FARVP FilmArray Respiratory Panel

Specimen Required

• Nasopharyngeal Swab-Viral transport media (VTM) •BAL-Sterile container

Specimen Minimum Volume

• Nasopharyngeal Swab • 0.5ml BAL

Specimen Stability Information

•NP Swab- Must be refrigerated and received within 3 days •BAL-Must be refrigerated and received within 24 hours

Specimen Instructions

• Nasopharyngeal Swab- Collect according to standard technique and immediately place swab into 3ml viral transport media.

SETUP SCHEDULE

Daily

INCLUDES

Molecular detection of 18 respiratory viruses and bacteria including: Adenovirus, Coronavirus HKU1, Coronavirus NL63, Coronavirus 229E, Coronavirus OC43, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza A/H1, Influenza A/H3, Influenza A/H1-2009, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3, Parainfluenza Virus 4, Respiratory Syncytial Virus, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae

TRANSPORT/STORAGE CONDITION

Refrigerated

Method Description

Molecular detection of Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, Human Metapneumovirus, Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype H1-2009, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3, Parainfluenza Virus 4, Human Rhinovirus/Enterovirus, Respiratory Syncytial Virus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.

Analytic Time

1-2 Days

Reject Due To

Specimen not received in appropriate transport container or at appropriate temperature.

Limitations

This assay cannot differentiate Rhinovirus/Enterovirus. If necessary for patient care, a positive result for Rhinovirus/Enterovirus may be followed-up using an alternate method.
Viral and bacterial nucleic acids may persist even though no viable organism is present. Detection of nucleic acid does not imply that the corresponding organisms are infectious or are the causative agents of clinical symptoms.
A negative result does not exclude the possibility of viral or bacterial infection. Performance characteristics may vary with circulating strains. The assay may not be able to distinguish between existing viral strains and new variants as they emerge.
The performance of this test has not been established in individuals who received influenza vaccine. Recent administration of a nasal influenza vaccine may cause false positive results for Influenza A and/or Influenza B.

Category

Molecular